ANTHONY
COMMERCIALLY INSURED
As an eligible, commercially insured patient, Anthony pays $0 per month for his RINVOQ prescription.*
Find out howUS-MULT-250253
For adults with giant cell arteritis (GCA) and for adult TNFi-IR patients with: moderate to severe active rheumatoid arthritis (RA); active psoriatic arthritis (PsA); active ankylosing spondylitis (AS); or active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation
WARNING: Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis
PREFERRED* Coverage Means
Affordability Options For Your Eligible Patients‡
Your eligible, commercially insured patients may pay as little as $0 per month with the RINVOQ Complete Savings Card.§
*RINVOQ is on a preferred tier or otherwise has preferred status on the plan's formulary.
†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
‡Based upon paid Commercial claims data from national data providers for a filled RINVOQ prescription for RA, PsA, AS, nr-axSpA, and GCA for the period May 2025-April 2026, inclusive of savings card redemptions.5
Patient’s actual out-of-pocket cost may vary depending on their insurance coverage and eligibility for support programs. Patient’s actual out-of-pocket cost may vary depending on their insurance coverage and eligibility for support programs.
§RINVOQ Complete Savings Card Terms and Conditions Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com or call 1.800.2RINVOQ for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy
AS=ankylosing spondylitis; IR=intolerance or inadequate response; GCA=giant cell arteritis; nr-axSpA=non-radiographic axial spondyloarthritis; PsA=psoriatic arthritis; RA=rheumatoid arthritis; TNFi=tumor necrosis factor inhibitor.
Results ends here
Results ends here
Preferred means RINVOQ is on a preferred tier or otherwise has preferred status on the plan’s formulary.
AS=active ankylosing spondylitis*; IR=intolerance or inadequate response; nr-axSpA=active non-radiographic axial spondyloarthritis†; PsA=active psoriatic arthritis*; RA=moderate to severe rheumatoid arthritis*; TNFi=tumor necrosis factor inhibitor.
*In adult TNFi-IR patients.
†In adult TNFi-IR patients with objective signs of inflammation.
ANTHONY
As an eligible, commercially insured patient, Anthony pays $0 per month for his RINVOQ prescription.*
Find out how
CHERYL
As a standard Medicare Part D patient enrolled in the Medicare Prescription Payment Plan, Cheryl pays $175 per month for all her prescriptions.6
Find out how
JOEY
As a Medicare Part D Extra Help patient, Joey pays $12.65 per prescription for RINVOQ.7
Find out howFinal patient out-of-pocket costs may vary based on a number of factors, including but not limited to a patient's insurance coverage, plan design, and Medicare Extra Help qualified enrollment.
*RINVOQ Complete Savings Card Terms and Conditions Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com or call 1.800.2RINVOQ for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy
RINVOQ is indicated for the treatment of:
Limitations of Use: RINVOQ is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (bDMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.
REFERENCES: